VECTRON THERAPEUTICS AG has a total of 25 patent applications. Its first patent ever was published in 1999. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CYTRAN LTD, TEDDER THOMAS F and APOTECH R & D SA.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 9 | |
#2 | WIPO (World Intellectual Property Organization) | 9 | |
#3 | Australia | 4 | |
#4 | Canada | 1 | |
#5 | Germany | 1 | |
#6 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Environmental technology | |
#5 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Climate change adaptation technologies | |
#5 | Analysing materials | |
#6 | Heterocyclic compounds | |
#7 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Mueller Rolf | 10 |
#2 | Kontermann Roland | 9 |
#3 | Graser Andreas | 8 |
#4 | Fahr Alfred | 6 |
#5 | Hoellig Peter | 4 |
#6 | Miller Daniel | 3 |
#7 | Brummerhop Harm | 3 |
#8 | Achenbach Tatjana | 3 |
#9 | Bach Thorsten | 3 |
#10 | Muller Rolf | 3 |
Publication | Filing date | Title |
---|---|---|
EP1557429A1 | Site-directed coupling of proteins | |
EP1550458A1 | Synergistic liposomal adjuvants | |
EP1547581A1 | Liposomal vaccine for the treatment of human hematological malignancies | |
EP1537858A1 | Drug delivery vehicles and uses thereof | |
EP1538164A1 | RGD targeting moiety its production and use | |
EP1230917A1 | Invasomes for the therapy of illnesses, their manufacture and use | |
AU2960502A | Multimeric single-chain antibody with multiple antigen binding | |
WO0241870A2 | Production and use of a targeted diagnostic system | |
WO0220614A2 | Endoglin-specific polypeptide, production and use thereof | |
DE19936789A1 | New pyrrolidinols and their use in tumor therapy |